EXOC3 Recombinant Monoclonal Antibody

EXOC3, also known as Sec6, serves as an essential component of the exocyst complex, an octameric protein assembly that orchestrates the tethering of secretory vesicles to the plasma membrane prior to fusion. This process is fundamental to polarized exocytosis, cell migration, and cytokinesis, making EXOC3 a protein of considerable interest in studies of membrane trafficking, cancer cell invasion, and epithelial polarity.

This recombinant monoclonal antibody, generated in rabbit and derived from clone 11B2, offers the reproducibility and consistency that demanding experimental workflows require. Because the antibody sequence is defined and produced recombinantly, researchers can expect uniform performance across lots, eliminating the variability that can complicate long-term studies or multi-site collaborations. The antibody was raised against a synthetic peptide derived from human EXOC3 and purified by affinity chromatography, ensuring high specificity for your target.

Validation across multiple platforms demonstrates genuine experimental flexibility. Immunohistochemistry performed on paraffin-embedded human cervical cancer and skeletal muscle tissues at 1:100 dilution reveals clear target detection using standard citrate buffer antigen retrieval. For cellular studies, immunofluorescence staining in HepG2 cells shows distinct localization patterns when used at 1:50, while flow cytometry analysis of HeLa cells confirms robust signal separation from isotype controls at 1:100 dilution.

Whether you are investigating exocyst function in tumor progression, exploring vesicle trafficking mechanisms, or characterizing EXOC3 expression patterns across human tissues, this antibody provides a reliable tool validated across immunohistochemical, immunofluorescence, and flow cytometric applications.